The SafeBoosC phase II randomised clinical trial: a treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants
Pellicer, Adelina × Greisen, Gorm Benders, Manon Claris, Olivier Dempsey, Eugene Fumagalli, Monica Gluud, Christian Hagmann, Cornelia Hellström-Westas, Lena Hyttel-Sorensen, Simon Lemmers, Petra Naulaers, Gunnar Pichler, Gerhard Roll, Claudia van Bel, Frank van Oeveren, Wim Skoog, Maria Wolf, Martin Austin, Topun #
S. Karger AG
Neonatology vol:104 issue:3 pages:171-8
Near-infrared spectroscopy-derived regional tissue oxygen saturation of haemoglobin (rStO2) reflects venous oxygen saturation. If cerebral metabolism is stable, rStO2 can be used as an estimate of cerebral oxygen delivery. The SafeBoosC phase II randomised clinical trial hypothesises that the burden of hypo- and hyperoxia can be reduced by the combined use of close monitoring of the cerebral rStO2 and a treatment guideline to correct deviations in rStO2 outside a predefined target range.